Bosakitug Misses Phase 2 Endpoints in Atopic Dermatitis Despite Target Engagement
Aclaris' anti-TSLP antibody bosakitug missed primary and secondary EASI endpoints in phase 2 atopic dermatitis despite confirmed target engagement and Th1/Th2/Th17 biomarker reductions.
